Bluestone Center for Clinical Research, New York University College of Dentistry, 421 First Avenue, 233W, New York, NY, 10010, USA; Department of Molecular Pathobiology, New York University College of Dentistry, 345 E. 24th street, New York, NY, 10010, USA; USA Elixiria Biotech Inc, Hartsdale, NY, 10530, USA; Shanghai Elixiria Biotech Co. Ltd, 578 Yingkou Road, Yangpu District, Shanghai, 200433, China.
Shanghai Elixiria Biotech Co. Ltd, 578 Yingkou Road, Yangpu District, Shanghai, 200433, China.
Neuropharmacology. 2022 Nov 1;218:109233. doi: 10.1016/j.neuropharm.2022.109233. Epub 2022 Aug 22.
Chemotherapy-induced neuropathic pain (CINP) is a debilitating and difficult-to-treat side effect of chemotherapeutic drugs. CINP is marked with oxidative stress and neuronal hypersensitivities. The peroxisome proliferator-activated receptor gamma (PPARγ) is a transcription factor that regulates genes involved in oxidative stress and inflammation. We hypothesize that PPARγ agonists are protective against CIPN by reducing oxidative stress and inhibiting neuronal hypersensitivities. To test our hypothesis, acute or chronic CIPN was introduced by short or long-term treatment of oxaliplatin in BALB/c mice. CIPN mice were treated with either a novel blood-brain barrier (BBB) penetrable PPARγ agonist ELB00824, or a BBB non-penetrable PPARγ agonist pioglitazone, or vehicle. Cold allodynia, mechanical allodynia, motor coordination, sedation and addiction were measured with dry ice, von Frey filaments, beam-walking tests, and conditioned place preference, respectively. Oxidative stress was accessed by measuring byproducts of protein oxidation (carbonyl and 3-Nitrotyrosine) and lipid peroxidation [Thiobarbituric acid reactive substances (TBARS)], as wells as gene expression of Cat, Sod2, Ppargc1a. The effects of ELB00824 on nociceptor excitability were measured using whole-cell electrophysiology of isolated dorsal root ganglion neurons. Preemptive ELB00824, but not pioglitazone, reduced oxaliplatin-induced cold and mechanical allodynia and oxidative stress. ELB0824 suppressed oxaliplatin-induced firing in IB4 neurons. ELB00824 did not cause motor discoordination or sedation/addiction or reduce the antineoplastic activity of oxaliplatin (measured with an MTS-based cell proliferation assay) in a human colon cancer cell line (HCT116) and a human oral cancer cell line (HSC-3). Our results demonstrated that ELB00824 prevents oxaliplatin-induced pain, likely via inhibiting neuronal hypersensitivities and oxidative stress.
化疗诱导性神经病理性疼痛(CINP)是化疗药物的一种使人虚弱且难以治疗的副作用。CINP 的特征是氧化应激和神经元超敏。过氧化物酶体增殖物激活受体γ(PPARγ)是一种转录因子,可调节涉及氧化应激和炎症的基因。我们假设 PPARγ 激动剂通过降低氧化应激和抑制神经元超敏来预防 CIPN。为了验证我们的假设,通过短期或长期奥沙利铂处理 BALB/c 小鼠来引入急性或慢性 CIPN。用新型血脑屏障(BBB)可穿透的 PPARγ 激动剂 ELB00824 或 BBB 不可穿透的 PPARγ 激动剂吡格列酮或载体处理 CIPN 小鼠。用干冰、冯弗雷纤维、梁行走试验和条件性位置偏爱分别测量冷感觉过敏、机械感觉过敏、运动协调、镇静和成瘾。通过测量蛋白质氧化(羰基和 3-硝基酪氨酸)和脂质过氧化的副产物[硫代巴比妥酸反应物质(TBARS)]以及 Cat、Sod2、Ppargc1a 的基因表达来评估氧化应激。使用分离的背根神经节神经元的全细胞膜片钳记录测量 ELB00824 对伤害感受器兴奋性的影响。预先给予 ELB00824 而非吡格列酮可减轻奥沙利铂引起的冷和机械感觉过敏以及氧化应激。ELB0824 抑制奥沙利铂诱导的 IB4 神经元放电。ELB00824 不会引起运动协调障碍或镇静/成瘾,也不会降低奥沙利铂(用人结肠癌细胞系(HCT116)和人口腔癌细胞系(HSC-3)中的基于 MTS 的细胞增殖测定法测量)的抗肿瘤活性。我们的结果表明,ELB00824 可预防奥沙利铂引起的疼痛,可能是通过抑制神经元超敏和氧化应激。